NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-03 15:36இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Concord Biotech Reports Q2 FY27 Earnings Call Transcript: Revenue Up 25%, EBITDA Margin at 33.8%
Concord Biotech released the earnings call transcript for Q2 & H1 FY27, reporting a 25% YoY revenue growth for Q2 FY27 and 26% for H1 FY27. Reported EBITDA margin for Q2 stood at 33.8%, compressed by a ~400 bps YoY gross margin drop due to elevated raw material costs like solvents. Segmentally, API revenue grew 30% YoY while formulations grew 6%, supported by broad-based growth in immunosuppressants, anti-infectives, and a near-doubling in oncology. Capacity utilization remains varied, with Unit I at 75%, Unit III at 55%, Unit II at 21%, and Unit IV at 5%.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the detailed management transcript for the Q2 & H1 FY27 earnings conference call held on October 28, 2026.
ஏன் இது முக்கியம்Provides detailed operational metrics including capacity utilization across units, margin pressure factors (solvents, power/fuel), and progress on US subsidiary Stellon and injectables.
📅 குறுகிய காலம்Transcript filing is procedural after earnings; attention remains on H2 performance and margin stabilization after recent solvent price inflation.
📈 நீண்ட காலம்Long-term scaling depends on improving utilization at Unit II and Unit IV injectables from 21% and 5% respectively, and expanding US presence via Stellon.
⚠ அபாய எச்சரிக்கைகள்
Gross margin pressure of ~400 bps due to volatile solvent and raw material prices
Underutilization at new facilities (Unit IV at 5%, Unit II at 21%) weighing on current margins
👀 கவனிக்க வேண்டியவை
Track the ramp-up and commercial contracts at the newly commissioned Unit II (21% utilization) and Unit IV injectables facility (5% utilization), along with margin recovery toward the 38-40% target as US subsidiary Stellon gains commercial traction in H2.
Concord Biotech Q2FY27 Revenue Up 25.1% to ₹309.1 Cr; Announces 1:1 Bonus Issue
Concord Biotech reported a 25.1% YoY increase in consolidated revenue from operations for Q2FY27 to ₹309.1 Cr, driven primarily by strong domestic growth (+42%) and API sales (+30%). Consolidated EBITDA rose 18.0% YoY to ₹104.4 Cr, while PAT grew 10.3% YoY to ₹69.6 Cr, though EBITDA margins contracted by 200 bps to 33.8% due to higher raw material costs and product mix changes. The company also announced a 1:1 bonus share issue and highlighted recent USFDA clearance at its Unit II formulation facility with only one procedural observation. Additionally, it expanded into dermatology with the launch of its Inspira division and received 2 ANDA approvals (Tofacitinib and MMF OS).
உச்சம் நம்பிக்கை
என்ன மாறியதுConcord Biotech reported Q2FY27 earnings with 25% revenue growth, approved a 1:1 bonus share issue, and launched a new dermatology division named Inspira.
ஏன் இது முக்கியம்Demonstrates robust revenue momentum in core fermentation APIs, although input cost pressures diluted margins by 200 bps YoY.
📅 குறுகிய காலம்Positive sentiment likely driven by healthy top-line growth (25.1% YoY) and the 1:1 bonus issue announcement, tempered slightly by gross margin compression.
📈 நீண்ட காலம்Structural growth remains supported by its 1,250 m³ fermentation capacity, expanding ANDA approvals, clean USFDA track record, and commercialization of new segments like injectables and dermatology.
⚠ அபாய எச்சரிக்கைகள்
Raw material cost inflation and adverse product mix leading to a 400 bps YoY dip in gross margins
Customer concentration risk with top 10 customers accounting for 37.6% of FY26 revenue
👀 கவனிக்க வேண்டியவை
Track the record date and execution of the 1:1 bonus issue, alongside margin recovery and capacity utilization ramp-up at the injectable facility.
Concord Biotech Approves Q2 FY27 Results; Sets Nov 04, 2026 Record Date for Bonus Issue
Concord Biotech announced that its Board of Directors approved the unaudited financial results for the quarter and half-year ended September 30, 2026. The company fixed Wednesday, November 04, 2026, as the record date for determining eligible shareholders for the issue of bonus equity shares. Additionally, the Board approved the reconstitution of key board committees, including Audit, Nomination & Remuneration, and Risk Management committees.
உச்சம் நம்பிக்கை
என்ன மாறியதுFormal fixation of the bonus share allotment record date to November 04, 2026, alongside reconstitution of core Board committees.
ஏன் இது முக்கியம்The bonus issue increases share liquidity without altering equity fundamentals, while the H1 cash flow profile shows continued capital deployment into plant and equipment.
Record Date for Bonus Shares: நவம்பர் 04, 2026H1 Net Operating Cash Flow: Rs 16,950.29 lakhsH1 Capex (PPE & Intangibles): Rs 5,894.84 lakhsCapex vs TTM Revenue: ~5.3%
📅 குறுகிய காலம்Trading action may reflect price adjustment around the upcoming bonus record date of November 04, 2026.
📈 நீண்ட காலம்Long-term performance remains dependent on scaling capacity utilization at the new injectable facility and executing CDMO fermentation expansion.
⚠ அபாய எச்சரிக்கைகள்
Regulatory approval timelines (such as CDSCO Written Confirmations)
Export market geopolitical exposure
👀 கவனிக்க வேண்டியவை
Track the ex-bonus date leading up to November 04, 2026, and examine the detailed revenue and margin progression in the Q2 results against management's 25% growth guidance.
Concord Biotech's Board of Directors has approved a 1:1 bonus issue, granting 1 bonus equity share of Rs 1 each for every 1 existing share held. The issue will capitalize Rs 10.46 crore from the share premium account, which stood at Rs 81.97 crore as of March 31, 2026. Consequently, total paid-up equity shares will double from 10,46,16,204 to 20,92,32,408. The company also increased its authorized share capital from Rs 11 crore to Rs 22 crore, with bonus shares slated for dispatch by November 22, 2026, subject to shareholder approval.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company approved a 1:1 bonus share issue and doubled its authorized share capital to Rs 22 crore.
ஏன் இது முக்கியம்A bonus issue increases stock liquidity and reduces nominal share price, making shares more accessible to retail investors without altering underlying enterprise fundamentals.
📅 குறுகிய காலம்Trading volume and retail participation may increase ahead of the record date; share price will adjust proportionately by half post-ex-date.
📈 நீண்ட காலம்Limited direct financial impact as bonus issues do not generate cash flow or alter business intrinsic value, though it reflects balance sheet capitalization.
⚠ அபாய எச்சரிக்கைகள்
Subject to shareholder approval
👀 கவனிக்க வேண்டியவை
Track the upcoming shareholder vote results and the announcement of the record date to determine eligibility for the bonus shares.
Concord Biotech Concludes USFDA Inspection at Unit II with 1 Minor Procedural Observation
The USFDA has concluded an inspection at Concord Biotech's formulation facility (Unit II) located in Valthera, Gujarat, on September 18, 2026. The inspection resulted in only 1 minor procedural observation that is not related to Good Manufacturing Practice (GMP). Management expects zero material impact on current business operations or existing supplies from the facility. The company plans to submit a comprehensive response to the USFDA within the stipulated regulatory timeline.
உச்சம் நம்பிக்கை
என்ன மாறியதுUSFDA completed its inspection of the Valthera Unit II formulation facility with a single minor non-GMP procedural observation.
ஏன் இது முக்கியம்A clean or low-risk USFDA inspection outcome removes regulatory overhang on export supplies and product approvals from this critical formulation facility.
Observations issued: 1Nature of observation: procedural, not related to GMPInspection completion date: செப்டம்பர் 18, 2026
📅 குறுகிய காலம்Positive sentiment relief as the facility avoids severe GMP or 483 compliance issues, ensuring business continuity.
📈 நீண்ட காலம்Supports the company's long-term export expansion strategy into regulated US markets for formulation products.
⚠ அபாய எச்சரிக்கைகள்
USFDA acceptance of the corrective response is pending formal final classification (EIR)
👀 கவனிக்க வேண்டியவை
Track the formal receipt of the Establishment Inspection Report (EIR) or official USFDA classification (such as VAI/NAI) following the company's response.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
26% Revenue Growth in Q1 FY27; API Segment Surges 42% YoY
Concord Biotech reported a strong recovery in Q1 FY27 with revenues reaching ₹257 cr, a 26.2% YoY increase compared to ₹204 cr in Q1 FY26. The growth was primarily driven by the API segment, which grew 42% YoY to ₹219 cr, and a robust 46% surge in export revenues. Management has set an ambitious long-term target to reach ₹2,200 cr in API revenue over the next 5-6 years, more than doubling its current TTM revenue of ₹1,055 cr. The company is focusing on scaling its new injectable facility and its US front-end platform, Stellon Biotech, to sustain a 25% CAGR.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has moved past the regulatory and geopolitical headwinds of FY26, showing a sharp recovery in API sales and export momentum.
ஏன் இது முக்கியம்The strong Q1 performance validates the scalability of Concord's niche fermentation platform and its ability to maintain high margins (35% OPM) while expanding into regulated markets like the US and Brazil.
📅 குறுகிய காலம்The stock may see positive sentiment as the 26% revenue growth signals a turnaround from the previous year's stagnation.
📈 நீண்ட காலம்The structural shift toward injectables and direct US distribution, combined with a target to double API revenues, suggests significant long-term value creation if execution remains on track.
⚠ அபாய எச்சரிக்கைகள்
De-growth in the formulation segment during Q1
Geopolitical risks in the Middle East affecting government contracts
👀 கவனிக்க வேண்டியவை
Monitor the utilization levels of the new injectable facility and the revenue contribution from the US front-end platform (Stellon Biotech) in upcoming quarters. Track the execution of the 25% CAGR guidance as the company transitions from API-heavy to a more balanced API and formulation mix.
26% Revenue Growth in Q1 FY27; Exports Surge 46% YoY with Margin Expansion
Concord Biotech reported a strong start to FY27 with Q1 revenue growing 26.2% YoY to ₹257.5 cr, primarily driven by a 46% surge in export revenue. EBITDA margins expanded by 190 bps to 32.0%, while core EBITDA margins (excluding new facility startup costs) remained robust at 37%. The company achieved significant regulatory milestones, including USFDA approvals for two ANDAs and successful inspections by ANVISA (Brazil). However, the formulation segment saw a 23% YoY decline, contrasting with the 42% growth in the API business.
உச்சம் நம்பிக்கை
என்ன மாறியதுConcord has successfully pivoted back to growth after a challenging FY26, led by strong export demand and regulatory clearances for new products.
ஏன் இது முக்கியம்The results validate the company's niche moat in fermentation-based APIs and its ability to expand wallet share with global clients while maintaining high margins despite new facility startup costs.
📅 குறுகிய காலம்The stock may react positively to the strong export growth and margin expansion, reflecting a recovery from previous regulatory and geopolitical headwinds.
📈 நீண்ட காலம்The company is structurally well-positioned with a large fermentation capacity and a diversifying product mix (Injectables/CDMO) to sustain its 25% growth guidance over the next few years.
⚠ அபாய எச்சரிக்கைகள்
23% YoY decline in formulation revenue
Startup costs for new facilities weighing on consolidated margins
Geopolitical risks affecting specific government contracts
👀 கவனிக்க வேண்டியவை
Investors should monitor the utilization ramp-up at the new injectable facility and Stellon Biotech, which are critical for the 25% CAGR target. Additionally, track the recovery of the formulation segment and the impact of new ANDA launches on US market share.
Concord Biotech Q1 Results: Net Profit Up 39% YoY to ₹61.22 Cr; Revenue Grows 26%
Concord Biotech reported a strong year-on-year performance for Q1 FY27, with consolidated revenue rising 26.2% to ₹257.49 Cr compared to ₹203.99 Cr in Q1 FY26. Net profit grew 38.9% YoY to ₹61.22 Cr, reflecting improved operational efficiency in its niche fermentation API business. While YoY growth is robust, the company saw a sequential (QoQ) decline in revenue and profit by 21% and 30% respectively from the March 2026 quarter. The company also finalized the acquisition of Celliimune Biotech Private Limited on April 02, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுConcord Biotech reported its first-quarter results for FY27, showing significant YoY growth and the formal addition of Celliimune Biotech to its consolidated entity.
ஏன் இது முக்கியம்The results validate the company's growth trajectory in the high-margin fermentation API space. Maintaining a ~31% PBT margin despite sequential volatility is critical for its premium valuation (P/E of 56.4).
📅 குறுகிய காலம்The strong YoY growth figures are likely to be viewed positively by the market, though the sequential dip may temper immediate gains.
📈 நீண்ட காலம்The company's focus on complex fermentation and the ramp-up of the injectable facility supports its long-term 25% CAGR guidance. The low debt (₹1 Cr) and high ROCE (19%) provide a strong structural foundation.
⚠ அபாய எச்சரிக்கைகள்
Sequential decline in revenue and profit compared to Q4 FY26
Regulatory dependency on CDSCO renewals for Written Confirmations
Geopolitical risks affecting Middle East government contracts
👀 கவனிக்க வேண்டியவை
Monitor the utilization levels of the new injectable facility and the integration of Celliimune Biotech. Investors should watch for management's progress toward their 25% CAGR target and any updates on CDSCO renewal timelines which previously impacted sales.
₹7.55 Dividend and ₹500 Cr Loan Limit Proposed in Concord Biotech AGM Notice
Concord Biotech has scheduled its 41st AGM for July 31, 2026, proposing a final dividend of ₹7.55 per share (755% of face value) for FY26. A significant special resolution seeks approval to enhance limits for loans, guarantees, and securities to subsidiaries and associates up to ₹500 Crores. This limit represents approximately 24.7% of the company's current net worth of ₹2,019 Cr. The record date for dividend eligibility and voting has been fixed for July 24, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized its dividend payout for FY26 and is seeking shareholder approval to significantly increase its capacity to fund subsidiaries and joint ventures.
ஏன் இது முக்கியம்The ₹500 Cr loan limit indicates potential capital deployment towards growth initiatives in subsidiaries, while the dividend confirms a payout of approximately 30% of TTM PAT.
Dividend per share: ₹7.55Proposed Loan/Guarantee Limit: ₹500 கோடிLoan Limit vs Net Worth: ~24.7%ரெக்கார்ட் தேதி: ஜூலை 24, 2026AGM Date: ஜூலை 31, 2026
📅 குறுகிய காலம்The stock may see mild positive interest leading up to the July 24 record date due to the dividend yield (~0.6% at current price).
📈 நீண்ட காலம்The increased financial flexibility to support subsidiaries aligns with the company's strategy to scale its fermentation and injectable platforms for a 25% CAGR.
⚠ அபாய எச்சரிக்கைகள்
Related-party risks associated with loans to entities where directors may have interests
Utilization of the ₹500 Cr limit for non-core activities
👀 கவனிக்க வேண்டியவை
Investors should note the July 24 record date for dividend eligibility and monitor the AGM proceedings for management updates on the 25% CAGR growth target and injectable facility ramp-up.
Concord Biotech Unit-II Facility Clears Inspections by Kenya and Uganda Regulators
Concord Biotech has successfully completed inspections by the Pharmacy and Poisons Board (PPB) of Kenya and the National Drug Authority (NDA) of Uganda at its Unit-II formulation facility. The inspections were conducted over a seven-day period from June 18, 2026, to June 24, 2026. This regulatory clearance marks a significant milestone in the company's strategy to expand its global manufacturing and regulatory footprint. The successful outcome validates the facility's adherence to international quality standards, paving the way for increased exports to the African market.
முக்கிய அம்சங்கள்
Successful completion of inspections by Kenya's PPB and Uganda's NDA at the Unit-II formulation facility.The inspection process was conducted from June 18, 2026, to June 24, 2026.Strengthens the company's regulatory footprint and market access in the African pharmaceutical region.Reinforces the company's commitment to high-quality manufacturing standards and regulatory excellence.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward geographic diversification and export growth. Monitor for future product approvals and revenue contributions from these specific African markets.
Concord Biotech to Acquire 27.38% Stake in FSGE Renewable for Rs 6.3 Crore
Concord Biotech has entered into an agreement to acquire a 27.38% equity stake in FSGE Renewable Power Private Limited for a cash consideration of Rs 6.3 Crores. This strategic investment is aimed at setting up a hybrid renewable energy plant in Gujarat with 6.3 MW Wind and 6.3 MWp Solar capacity. The project will serve as a captive power source for the company's Limbasi facility, focusing on long-term reduction of energy costs. FSGE is currently a Special Purpose Vehicle (SPV) and is expected to allot shares within 60 days.
முக்கிய அம்சங்கள்
Acquisition of 27.38% equity stake in FSGE Renewable Power for Rs 6.3 Crores in cash.Installation of a hybrid power project with 6.3 MW Wind and 6.3 MWp Solar capacity in Gujarat.The project is dedicated to providing captive power for the company's Limbasi manufacturing facility.Investment aims to reduce the company's carbon footprint and lower long-term operational energy costs.FSGE is an SPV incorporated in August 2023 and has not yet commenced commercial operations.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward operational efficiency and ESG compliance which may improve margins over the long term. Monitor the project's completion timeline and its impact on power cost savings in future earnings reports.
Concord Biotech Completes ANVISA Inspection at Limbasi API Facility
Concord Biotech Limited has successfully completed an inspection by the Brazilian Health Regulatory Agency (ANVISA) at its Limbasi API manufacturing facility. The inspection was conducted over five days from June 8 to June 12, 2026. This successful outcome is a key milestone for the company's international expansion, facilitating entry into the large Brazilian pharmaceutical market. It reinforces the company's global regulatory footprint and adherence to high-quality manufacturing standards.
முக்கிய அம்சங்கள்
Successful completion of ANVISA inspection at the Limbasi API manufacturing facility.Inspection conducted by the Brazilian Health Regulatory Agency from June 8 to June 12, 2026.Enhances access to the Brazilian pharmaceutical market, one of the largest in the world.Strengthens the company's global manufacturing and regulatory footprint for its API business.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive regulatory development that paves the way for revenue growth in the Latin American region. Monitor for future product filings and approvals in the Brazilian market following this facility clearance.
Concord Biotech Gets USFDA Approval for Tofacitinib Tablets; Targets $500M US Market
Concord Biotech has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Tofacitinib Tablets in 5 mg and 10 mg strengths. The drug is indicated for several chronic conditions, including rheumatoid arthritis and ulcerative colitis. The estimated U.S. market size for these specific strengths is approximately $500 million, representing a significant revenue opportunity. This approval is a key milestone in the company's strategy to expand its presence in the U.S. and international pharmaceutical markets.
முக்கிய அம்சங்கள்
Received USFDA approval for Tofacitinib Tablets in 5 mg and 10 mg strengthsAddresses a U.S. market opportunity estimated at approximately $500 millionIndicated for treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative ColitisStrengthens the company's product portfolio and long-term growth strategy in the U.S. market
👀 கவனிக்க வேண்டியவை
This approval is a significant positive trigger for the stock as it opens up a large addressable market in the U.S. Investors should watch for the commercial launch timeline and subsequent market share gains.
Concord Biotech FY26 PAT Drops 30% to ₹260 Cr; Management Guides for >18% Growth in FY27
Concord Biotech reported a challenging FY26 with total revenue declining 12% to ₹829 crores and PAT falling 30% to ₹260 crores, primarily due to geopolitical headwinds and supply chain disruptions in the Middle East and Europe. Despite the decline, the company maintained a healthy adjusted EBITDA margin of 39% and remains debt-free with ₹414 crores in cash. Management has provided a positive outlook for FY27, expecting growth to exceed their historical 18% average as supply issues normalize and new facilities scale up.
முக்கிய அம்சங்கள்
FY26 Revenue declined 12% YoY to ₹829 crores, with Q4 witnessing a sharper 24% degrowth.Profit After Tax (PAT) for the full year stood at ₹260 crores, down 30% compared to the previous fiscal.Adjusted EBITDA margin (excluding new facility expenses) remained strong at 39%, though reported margin was 35%.Management guides for FY27 growth to be higher than the historical 18% average, supported by a strong H1 visibility.The company is debt-free with ₹414 crores in cash and has a peak revenue potential of ₹3,000 crores from existing units.
👀 கவனிக்க வேண்டியவை
Investors should focus on Q1 FY27 performance to confirm the management's turnaround guidance. While FY26 was impacted by temporary external factors, the company's strong balance sheet and new injectable/US subsidiary platforms provide a base for recovery.
Concord Biotech Secures USFDA Approval for Mycophenolate Mofetil; US Market Size $30 Million
Concord Biotech Limited has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. This immunosuppressant is used to prevent organ rejection in kidney, heart, or liver transplant patients. The U.S. market for this specific product is estimated at approximately US$ 30 million. This approval is a key step in the company's strategy to expand its presence and product offerings in the U.S. and international markets.
முக்கிய அம்சங்கள்
Received USFDA approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.The estimated U.S. market size for this product is approximately US$ 30 million.Indicated for prophylaxis of organ rejection in adult and pediatric transplant recipients.Strengthens the company's position in the U.S. market and supports long-term growth strategy.Approval follows Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that adds a new revenue stream in the U.S. market. Monitor the company's execution in capturing market share within this $30 million segment.
Concord Biotech FY26 PAT drops 30% to ₹259 Cr amid global headwinds and procurement delays
Concord Biotech reported a challenging FY26 with consolidated revenue declining 12% YoY to ₹1,054.9 crore and PAT falling 30% to ₹259.2 crore. EBITDA margins saw significant compression, dropping to 34.8% from 42.2% in the previous year, primarily due to geopolitical tensions in the Middle East and a shift in US procurement patterns from bulk to staggered orders. Despite the financial dip, the company successfully commercialized its injectable facility and established a US subsidiary, Stellon Biotech, to strengthen its global footprint.
முக்கிய அம்சங்கள்
Consolidated Revenue for FY26 decreased by 12% YoY to ₹1,054.9 crore compared to ₹1,200.1 crore in FY25.Full-year EBITDA margin contracted by 736 bps to 34.8%, while Q4FY26 margin stood at 36.4%.Net Profit (PAT) for the year declined by 30% YoY to ₹259.2 crore from ₹371.6 crore.API segment remains the primary driver contributing 79% of total revenue, with formulations at 21%.Management identified specific headwinds including a 3-month delay in EU regulatory confirmations and US Veterans Affairs tender delays.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution due to the significant margin contraction and revenue decline, though management's optimism for an FY27 recovery backed by new injectable and soft gel facilities warrants a 'watch' for signs of turnaround in the next two quarters.
Concord Biotech Recommends ₹7.55 Dividend and Approves FY26 Financial Results
Concord Biotech's Board has recommended a final dividend of ₹7.55 per equity share for the financial year ended March 31, 2026. The company reported audited financial results for both standalone and consolidated entities with an unmodified audit opinion from BSR & Co. LLP. To strengthen governance, the board appointed Mrs. Ekta Gupta as an Additional Independent Director for a five-year term. The record date for the dividend payout is set for July 24, 2026, subject to shareholder approval.
முக்கிய அம்சங்கள்
Recommended a dividend of ₹7.55 per equity share of face value ₹1 for FY 2025-26.Fixed July 24, 2026, as the record date for identifying shareholders eligible for the dividend payout.Appointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term starting June 1, 2026.Statutory auditors issued an unmodified opinion on the standalone and consolidated financial results for FY26.Appointed Manubhai & Shah LLP and Dalwadi & Associates as Internal and Cost Auditors respectively for FY27.
👀 கவனிக்க வேண்டியவை
Investors should ensure they hold the shares by the record date of July 24, 2026, to qualify for the ₹7.55 dividend. The clean audit report and addition of an independent director reflect stable corporate governance.
Concord Biotech Recommends ₹7.55 Dividend; Appoints New Independent Director
Concord Biotech's board has recommended a final dividend of ₹7.55 per share for FY 2025-26, subject to shareholder approval. The company reported audited financial results for the year ended March 31, 2026, receiving a clean, unmodified opinion from its statutory auditors. In a move to strengthen governance, Mrs. Ekta Gupta has been appointed as an Additional Independent Director for a five-year term. The board also finalized the appointment of new internal and cost auditors for the 2026-27 fiscal year.
முக்கிய அம்சங்கள்
Recommended a dividend of ₹7.55 per equity share of face value ₹1 each for FY 2025-26Fixed July 24, 2026, as the record date for identifying eligible shareholders for dividend paymentAppointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term starting June 1, 2026Statutory auditors BSR & Co. LLP issued an unmodified audit opinion for the FY26 financial resultsAppointed M/s. Manubhai & Shah LLP as Internal Auditor for the financial year 2026-27
👀 கவனிக்க வேண்டியவை
Investors should ensure they hold the stock before the July 24, 2026, record date to be eligible for the ₹7.55 dividend. The clean audit report and board expansion are positive indicators of corporate governance and stability.
Concord Biotech Recommends ₹7.55 Final Dividend; Sets Record Date for July 2026
Concord Biotech Limited has recommended a final dividend of ₹7.55 per equity share for the financial year 2025-26. The board has fixed July 24, 2026, as the record date to determine shareholder eligibility for the payout, pending approval at the upcoming Annual General Meeting. In addition to the dividend, the company reported audited financial results for FY26 with an unmodified audit opinion from BSR & Co. LLP. The board also strengthened its governance by appointing Mrs. Ekta Gupta as an Additional Independent Director for a five-year term.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹7.55 per equity share of face value ₹1 for FY 2025-26Fixed July 24, 2026, as the record date for identifying eligible shareholders for the dividendAppointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term effective June 1, 2026Statutory auditors issued an unmodified opinion on both standalone and consolidated financial results for FY26Approved the appointment of Manubhai & Shah LLP as Internal Auditors and Dalwadi & Associates as Cost Auditors for FY 2026-27
👀 கவனிக்க வேண்டியவை
Investors seeking dividend income should ensure they hold shares before the July 24, 2026 record date. The unmodified audit report and board expansion reflect positive corporate governance and financial stability.
Concord Biotech Acquires 100% Stake in Celliimune Biotech for Rs 66 Lakhs
Concord Biotech has completed the 100% acquisition of Celliimune Biotech Private Limited for a cash consideration of Rs 66 lakhs. Celliimune is a biopharmaceutical startup focused on pioneering DNA engineering for cancer therapeutics and cell/gene therapy solutions. While the target entity currently has nil turnover, the acquisition is a strategic move to enter the high-growth oncology research space. This transaction is classified as a related party transaction as the promoter group previously held a majority stake in the target entity.
முக்கிய அம்சங்கள்
Acquisition of 100% equity stake in Celliimune Biotech Private Limited for Rs 66,00,000Target entity focuses on DNA engineering for cancer therapeutics and cell/gene therapy solutionsCelliimune was incorporated in January 2025 and currently reports nil turnoverTransaction is a related party deal as promoters previously held majority controlAcquisition completed on April 02, 2026, via cash consideration
👀 கவனிக்க வேண்டியவை
Investors should view this as a long-term R&D play rather than an immediate revenue driver. Monitor for future updates on clinical breakthroughs or product development from this new subsidiary.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
